|
1
|
Kono K, Amemiya H, Sekikawa T, Iizuka H,
Takahashi A, Fujii H and Matsumoto Y: Clinicopathologic features of
gastric cancers producing alpha-fetoprotein. Dig Surg. 19:359–365;
discussion 365. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inoue M, Sano T, Kuchiba A, Taniguchi H,
Fukagawa T and Katai H: Long-term results of gastrectomy for
alpha-fetoprotein-producing gastric cancer. Br J Surg.
97:1056–1061. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li XD, Wu CP, Ji M, Wu J, Lu B, Shi HB and
Jiang JT: Characteristic analysis of α-fetoprotein-producing
gastric carcinoma in China. World J Surg Oncol. 11:2462013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koide N, Nishio A, Igarashi J, Kajikawa S,
Adachi W and Amano J: Alpha-fetoprotein-producing gastric cancer:
Histochemical analysis of cell proliferation, apoptosis and
angiogenesis. Am J Gastroenterol. 94:1658–1663. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takahashi Y, Ohta T and Mai M:
Angiogenesis of AFP producing gastric carcinoma: Correlation with
frequent liver metastasis and its inhibition by anti-AFP antibody.
Oncol Rep. 11:809–813. 2004.PubMed/NCBI
|
|
6
|
Yuan DD, Zhu ZX, Zhang X and Liu J:
Targeted therapy for gastric cancer: Current status and future
directions (Review). Oncol Rep. 35:1245–1254. 2016.PubMed/NCBI
|
|
7
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rüschoff J, Hanna W, Bilous M, Hofmann M,
Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2
testing in gastric cancer: A practical approach. Mod Pathol.
25:637–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okabe H, Hata H, Ueda S, Zaima M, Tokuka
A, Yoshimura T, Ota S, Kinjo Y, Yoshimura K and Sakai Y; Kyoto
University Surgical Oncology Group (KUSOG), : A phase II study of
neoadjuvant chemotherapy with S-1 and cisplatin for stage III
gastric cancer: KUGC03. J Surg Oncol. 113:36–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kinjo T, Taniguchi H, Kushima R, Sekine S,
Oda I, Saka M, Gotoda T, Kinjo F, Fujita J and Shimoda T:
Histologic and immunohistochemical analyses of
α-fetoprotein-producing cancer of the stomach. Am J Surg Pathol.
36:56–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
http://link.springer.com/article/10.1245/s10434-010-0985-4
|
|
14
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hamaguchi T, Shirao K, Yamamichi N, Hyodo
I, Koizumi W, Seki S, Imamura T, Honma H, Ohtsu A, Boku N, et al: A
phase II study of sequential methotrexate and 5-fluorouracil
chemotherapy in previously treated gastric cancer: A report from
the gastrointestinal Oncology group of the Japan clinical oncology
group, JCOG 9207 trial. Jpn J Clin Oncol. 38:432–437. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adachi Y, Tsuchihashi J, Shiraishi N,
Yasuda K, Etoh T and Kitano S: AFP-producing gastric carcinoma:
Multivariate analysis of prognostic factors in 270 patients.
Oncology. 65:95–101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Coiffier B, Thieblemont C, Van den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitsudomi T, Kosaka T, Endoh H, Horio Y,
Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small-cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kamei S, Kono K, Amemiya H, Takahashi A,
Sugai H, Ichihara F, Fujii H and Matsumoto Y: Evaluation of VEGF
and VEGF-C expression in gastric cancer cells producing
alpha-fetoprotein. J Gastroenterol. 38:540–547. 2003.PubMed/NCBI
|
|
22
|
Ichikura T, Tomimatsu S, Ohkura E and
Mochizuki H: Prognostic significance of the expression of vascular
endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J
Surg Oncol. 78:132–137. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koneri K, Hirono Y, Fujimoto D, Sawai K,
Morikawa M, Murakami M, Goi T, Iida A, Katayama K and Yamaguchi A:
Five-year survival of alpha-fetoprotein-producing gastric cancer
with synchronous liver metastasis: A case report. J Gastric Cancer.
13:58–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang YU, Wang L, Yang N, Gong X, Zhang YU
and Qin S: Successful multimodal therapy for an
α-fetoprotein-producing gastric cancer patient with simultaneous
liver metastases. Oncol Lett. 10:3021–3025. 2015.PubMed/NCBI
|
|
25
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blechacz BR, Smoot RL, Bronk SF, Werneburg
NW, Sirica AE and Gores GJ: Sorafenib inhibits signal transducer
and activator of transcription-3 signaling in cholangiocarcinoma
cells by activating the phosphatase shatterproof 2. Hepatology.
50:1861–1870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Edeline J, Boucher E, Rolland Y, Vauléon
E, Pracht M, Perrin C, Le Roux C and Raoul JL: Comparison of tumor
response by Response Evaluation Criteria in Solid Tumors (RECIST)
and modified RECIST in patients treated with sorafenib for
hepatocellular carcinoma. Cancer. 118:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R,
Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, et al:
Ramucirumab versus placebo as second-line treatment in patients
with advanced hepatocellular carcinoma following first-line therapy
with sorafenib (REACH): A randomised, double-blind, multicentre,
phase 3 trial. Lancet Oncol. 16:859–870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim C, Mulder K and Spratlin J: How
prognostic and predictive biomarkers are transforming our
understanding and management of advanced gastric cancer.
Oncologist. 19:1046–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
